IM Cannabis (IMCC) Competitors $0.24 +0.01 (+2.13%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. RNAZ, ACXP, FBLG, APVO, and PBMShould you buy IM Cannabis stock or one of its competitors? MarketBeat compares IM Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IM Cannabis include TransCode Therapeutics (RNAZ), Acurx Pharmaceuticals (ACXP), FibroBiologics (FBLG), Aptevo Therapeutics (APVO), and Psyence Biomedical (PBM). These companies are all part of the "pharmaceutical products" industry. IMCC vs. RNAZIMCC vs. ACXPIMCC vs. FBLGIMCC vs. APVOIMCC vs. PBMHow does IM Cannabis compare to TransCode Therapeutics?TransCode Therapeutics (NASDAQ:RNAZ) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations. Is RNAZ or IMCC more profitable? TransCode Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -875.35% -50.36% IM Cannabis -27.65%-585.96%-39.96% Do analysts rate RNAZ or IMCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer RNAZ or IMCC? In the previous week, TransCode Therapeutics had 1 more articles in the media than IM Cannabis. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for IM Cannabis. TransCode Therapeutics' average media sentiment score of 1.08 beat IM Cannabis' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TransCode Therapeutics Positive IM Cannabis Neutral Which has more volatility and risk, RNAZ or IMCC? TransCode Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Do insiders & institutionals believe in RNAZ or IMCC? 7.7% of IM Cannabis shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, RNAZ or IMCC? IM Cannabis has higher revenue and earnings than TransCode Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$34.66M-$50.33N/AIM Cannabis$50.91M0.03-$8.10M-$1.75N/A SummaryIM Cannabis beats TransCode Therapeutics on 8 of the 12 factors compared between the two stocks.How does IM Cannabis compare to Acurx Pharmaceuticals?Acurx Pharmaceuticals (NASDAQ:ACXP) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Which has more volatility & risk, ACXP or IMCC? Acurx Pharmaceuticals has a beta of -2.09, suggesting that its stock price is 309% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Do analysts recommend ACXP or IMCC? Acurx Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 1,397.58%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders and institutionals believe in ACXP or IMCC? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ACXP or IMCC? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for IM Cannabis. Acurx Pharmaceuticals' average media sentiment score of 0.79 beat IM Cannabis' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive IM Cannabis Neutral Is ACXP or IMCC more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Acurx Pharmaceuticals' return on equity of -153.92% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -153.92% -101.69% IM Cannabis -27.65%-585.96%-39.96% Which has preferable earnings & valuation, ACXP or IMCC? Acurx Pharmaceuticals has higher earnings, but lower revenue than IM Cannabis. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/AIM Cannabis$50.91M0.03-$8.10M-$1.75N/A SummaryAcurx Pharmaceuticals beats IM Cannabis on 10 of the 15 factors compared between the two stocks.How does IM Cannabis compare to FibroBiologics?IM Cannabis (NASDAQ:IMCC) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Which has more risk and volatility, IMCC or FBLG? IM Cannabis has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Does the media refer more to IMCC or FBLG? In the previous week, FibroBiologics had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score. Company Overall Sentiment IM Cannabis Neutral FibroBiologics Neutral Is IMCC or FBLG more profitable? FibroBiologics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-27.65% -585.96% -39.96% FibroBiologics N/A -767.07%-195.56% Do institutionals & insiders believe in IMCC or FBLG? 7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Comparatively, 9.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate IMCC or FBLG? FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 7,084.47%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, IMCC or FBLG? IM Cannabis has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$50.91M0.03-$8.10M-$1.75N/AFibroBiologicsN/AN/A-$18.65M-$6.93N/A SummaryIM Cannabis beats FibroBiologics on 8 of the 14 factors compared between the two stocks.How does IM Cannabis compare to Aptevo Therapeutics?Aptevo Therapeutics (NASDAQ:APVO) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Which has more volatility & risk, APVO or IMCC? Aptevo Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Does the media prefer APVO or IMCC? In the previous week, Aptevo Therapeutics had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 0 mentions for IM Cannabis. Aptevo Therapeutics' average media sentiment score of 0.33 beat IM Cannabis' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aptevo Therapeutics Neutral IM Cannabis Neutral Is APVO or IMCC more profitable? Aptevo Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Aptevo Therapeutics' return on equity of -198.50% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -198.50% -117.06% IM Cannabis -27.65%-585.96%-39.96% Do insiders and institutionals believe in APVO or IMCC? 8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend APVO or IMCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation & earnings, APVO or IMCC? IM Cannabis has higher revenue and earnings than Aptevo Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo TherapeuticsN/AN/A-$25.97M-$197.60N/AIM Cannabis$50.91M0.03-$8.10M-$1.75N/A SummaryAptevo Therapeutics beats IM Cannabis on 8 of the 14 factors compared between the two stocks.How does IM Cannabis compare to Psyence Biomedical?Psyence Biomedical (NASDAQ:PBM) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings. Do insiders & institutionals believe in PBM or IMCC? 77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer PBM or IMCC? In the previous week, Psyence Biomedical's average media sentiment score of 1.00 beat IM Cannabis' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Overall Sentiment Psyence Biomedical Positive IM Cannabis Neutral Which has preferable valuation & earnings, PBM or IMCC? Psyence Biomedical has higher earnings, but lower revenue than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPsyence BiomedicalN/AN/A$1.01M$25.340.17IM Cannabis$50.91M0.03-$8.10M-$1.75N/A Which has more volatility and risk, PBM or IMCC? Psyence Biomedical has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Do analysts rate PBM or IMCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is PBM or IMCC more profitable? Psyence Biomedical has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Psyence Biomedical's return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Psyence BiomedicalN/A N/A N/A IM Cannabis -27.65%-585.96%-39.96% SummaryPsyence Biomedical beats IM Cannabis on 8 of the 11 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition ExportMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$8.36B$6.37B$12.33BDividend YieldN/A2.49%2.79%5.33%P/E Ratio-0.1416.0020.9125.63Price / Sales0.036.52545.0185.20Price / CashN/A17.2044.1356.16Price / Book-0.404.0710.017.05Net Income-$8.10M$224.05M$3.55B$335.04M7 Day Performance3.88%5.52%4.69%2.50%1 Month Performance-29.90%-1.79%1.40%1.32%1 Year Performance-86.46%1.29%36.64%35.53% IM Cannabis Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.4874 of 5 stars$0.24+2.1%N/A-86.2%$1.49M$50.91MN/A340Gap UpRNAZTransCode Therapeutics0.561 of 5 stars$6.97+3.6%N/A-22.7%$6.17MN/AN/A9Positive NewsEarnings ReportACXPAcurx Pharmaceuticals2.4223 of 5 stars$1.99-2.9%$31.00+1,457.8%-76.5%$5.85MN/AN/A3Gap DownFBLGFibroBiologics2.8956 of 5 stars$1.13+2.7%$74.00+6,448.7%-94.3%$5.73MN/AN/A10APVOAptevo Therapeutics1.2033 of 5 stars$4.76-1.4%N/A-96.3%$5.71MN/AN/A50News Coverage Related Companies and Tools Related Companies RNAZ Competitors ACXP Competitors FBLG Competitors APVO Competitors PBM Competitors FLGC Competitors CDIO Competitors ENTO Competitors RDHL Competitors APM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
